Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension

Audio playback of Investors Presentation

Update on R&D Pipeline

SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis

SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)

Announcement - Receipt of reclassification approval from BSE

Announcement - Receipt of reclassification approval from NSE

Update on NCE and NDDS Programs

SPARC Licenses ELEPSIATM XR (Levetiracetam ER Tablets) to Sun Pharma

Update on XELP ROST and Elepsia XRT